MX2012003408A - Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2. - Google Patents
Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2.Info
- Publication number
- MX2012003408A MX2012003408A MX2012003408A MX2012003408A MX2012003408A MX 2012003408 A MX2012003408 A MX 2012003408A MX 2012003408 A MX2012003408 A MX 2012003408A MX 2012003408 A MX2012003408 A MX 2012003408A MX 2012003408 A MX2012003408 A MX 2012003408A
- Authority
- MX
- Mexico
- Prior art keywords
- abt
- crystalline forms
- solvates
- related diseases
- protein related
- Prior art date
Links
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 title abstract 2
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000012453 solvate Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 230000002424 anti-apoptotic effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 abstract 1
- 229950004847 navitoclax Drugs 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24405109P | 2009-09-20 | 2009-09-20 | |
| PCT/US2010/048949 WO2011034934A1 (en) | 2009-09-20 | 2010-09-15 | Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012003408A true MX2012003408A (es) | 2012-08-03 |
Family
ID=43064468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012003408A MX2012003408A (es) | 2009-09-20 | 2010-09-15 | Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8362014B2 (enExample) |
| EP (1) | EP2477972A1 (enExample) |
| JP (2) | JP2013505249A (enExample) |
| KR (1) | KR20120085781A (enExample) |
| CN (2) | CN102695702A (enExample) |
| AU (1) | AU2010295717B2 (enExample) |
| BR (1) | BR112012006252A2 (enExample) |
| CA (1) | CA2771984A1 (enExample) |
| IL (1) | IL218403A0 (enExample) |
| MX (1) | MX2012003408A (enExample) |
| NZ (1) | NZ598461A (enExample) |
| RU (1) | RU2551376C2 (enExample) |
| TW (1) | TWI488853B (enExample) |
| WO (1) | WO2011034934A1 (enExample) |
| ZA (1) | ZA201202891B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2558434T3 (es) | 2008-11-07 | 2016-02-04 | Amgen Research (Munich) Gmbh | Tratamiento de leucemia linfoblástica aguda |
| HRP20150400T1 (hr) * | 2008-11-07 | 2015-05-08 | Amgen Research (Munich) Gmbh | Lijeäśenje pedijatrijske akutne limfoblastiäśne leukemije |
| US8728516B2 (en) | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| US20100280031A1 (en) * | 2009-04-30 | 2010-11-04 | Paul David | Lipid formulation of apoptosis promoter |
| US8362013B2 (en) * | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
| TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
| TWI471321B (zh) | 2009-06-08 | 2015-02-01 | 亞培公司 | Ｂｃｌ－２族群抑制劑之口服醫藥劑型 |
| MX2012003408A (es) | 2009-09-20 | 2012-08-03 | Abbott Lab | Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2. |
| CA2780177A1 (en) * | 2009-12-22 | 2011-06-30 | Abbott Laboratories | Abt-263 capsule |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| CA2900322C (en) * | 2013-02-21 | 2019-03-26 | Pfizer Inc. | Solid forms of the selective cdk4/6 inhibitor compound acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8h-pyrido[2,3-d]pyrimidin-7-one |
| US20160022708A1 (en) | 2013-03-14 | 2016-01-28 | St. Jude Children's Research Hospital | Methods and compositions for the treatment of glutamine-addicted cancers |
| JP2016516808A (ja) * | 2013-04-21 | 2016-06-09 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． | Ｂｃｌ−ｘＬおよび／またはＢｃｌ−ｗの活性および／または量を下方制御するための薬剤 |
| CA2939121C (en) | 2014-01-28 | 2020-11-24 | Mayo Foundation For Medical Education And Research | Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease |
| WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| WO2015157120A1 (en) * | 2014-04-06 | 2015-10-15 | Abraxis Bioscience, Llc | Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer |
| TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| US20180133212A1 (en) | 2016-11-03 | 2018-05-17 | Gilead Sciences, Inc. | Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer |
| TR201703149A2 (tr) * | 2017-03-01 | 2018-09-21 | Univ Yeditepe | Kemoterapi̇k i̇laç kompozi̇syonu |
| CN108727387B (zh) * | 2018-07-25 | 2021-03-16 | 天津大学 | 依鲁替尼乙酸异丙酯溶剂化合物及其制备方法 |
| CN109053738B (zh) * | 2018-08-29 | 2020-10-16 | 浙江工业大学 | 一种依鲁替尼的溶剂化物及其制备方法 |
| JP7417356B2 (ja) | 2019-01-25 | 2024-01-18 | 株式会社ソニー・インタラクティブエンタテインメント | ロボット制御システム |
| JP2022553820A (ja) | 2019-11-05 | 2022-12-26 | アッヴィ・インコーポレイテッド | 骨髄線維症及びｍｐｎ関連障害をナビトクラクスで処置する際に使用するための投与レジメン |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2713507A (en) | 1948-10-04 | 1955-07-19 | Garlinghouse Brothers | Concrete bucket |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US7075365B1 (en) | 2004-04-22 | 2006-07-11 | Altera Corporation | Configurable clock network for programmable logic device |
| DK1888550T3 (da) * | 2005-05-12 | 2014-09-29 | Abbvie Bahamas Ltd | Apoptosepromotorer |
| MX2009002422A (es) * | 2006-09-05 | 2009-03-20 | Abbott Lab | Inhibidores bcl para tratar exceso de plaquetas. |
| JP4202380B2 (ja) * | 2006-10-17 | 2008-12-24 | シャープ株式会社 | 画像形成装置 |
| CN101939008A (zh) | 2007-12-06 | 2011-01-05 | 雅培制药有限公司 | 用于治疗癌症的abt-263经口组合物 |
| CN101220008B (zh) * | 2008-01-21 | 2011-04-27 | 中国科学院广州生物医药与健康研究院 | 化合物abt-263的合成方法 |
| US8168784B2 (en) * | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| US8140876B2 (en) * | 2009-01-16 | 2012-03-20 | International Business Machines Corporation | Reducing power consumption of components based on criticality of running tasks independent of scheduling priority in multitask computer |
| US8728516B2 (en) | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| US20100278921A1 (en) | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
| JP2010259520A (ja) | 2009-04-30 | 2010-11-18 | Motoji Ono | 搬送機構、トレッドミル及びコンベア |
| US20100297194A1 (en) | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
| US8362013B2 (en) * | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
| US20110047552A1 (en) * | 2009-05-11 | 2011-02-24 | Raytheon Bbn Technologies Corp. | Energy-aware process environment scheduler |
| US8291422B2 (en) * | 2009-05-11 | 2012-10-16 | Bbn Technologies Corp. | Energy-aware computing environment scheduler |
| MX2012003408A (es) | 2009-09-20 | 2012-08-03 | Abbott Lab | Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2. |
| CN101798292A (zh) | 2010-03-29 | 2010-08-11 | 无锡好芳德药业有限公司 | ABT-263衍生的新型Bcl-2蛋白抑制剂的制备 |
-
2010
- 2010-09-15 MX MX2012003408A patent/MX2012003408A/es unknown
- 2010-09-15 US US12/882,576 patent/US8362014B2/en active Active
- 2010-09-15 BR BR112012006252A patent/BR112012006252A2/pt not_active IP Right Cessation
- 2010-09-15 CN CN2010800417753A patent/CN102695702A/zh active Pending
- 2010-09-15 AU AU2010295717A patent/AU2010295717B2/en not_active Ceased
- 2010-09-15 CA CA2771984A patent/CA2771984A1/en not_active Abandoned
- 2010-09-15 EP EP10757361A patent/EP2477972A1/en not_active Withdrawn
- 2010-09-15 CN CN201610194338.4A patent/CN105820138A/zh active Pending
- 2010-09-15 NZ NZ598461A patent/NZ598461A/en not_active IP Right Cessation
- 2010-09-15 KR KR1020127010148A patent/KR20120085781A/ko not_active Ceased
- 2010-09-15 RU RU2012115851/04A patent/RU2551376C2/ru not_active IP Right Cessation
- 2010-09-15 WO PCT/US2010/048949 patent/WO2011034934A1/en not_active Ceased
- 2010-09-15 JP JP2012529878A patent/JP2013505249A/ja active Pending
- 2010-09-20 TW TW099131885A patent/TWI488853B/zh not_active IP Right Cessation
-
2011
- 2011-07-28 US US13/193,013 patent/US8513243B2/en not_active Expired - Fee Related
-
2012
- 2012-02-29 IL IL218403A patent/IL218403A0/en unknown
- 2012-04-19 ZA ZA2012/02891A patent/ZA201202891B/en unknown
-
2015
- 2015-07-17 JP JP2015142670A patent/JP2015232006A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010295717B2 (en) | 2014-09-11 |
| NZ598461A (en) | 2013-12-20 |
| AU2010295717A1 (en) | 2012-03-22 |
| US20110294811A1 (en) | 2011-12-01 |
| TW201116526A (en) | 2011-05-16 |
| US20110071151A1 (en) | 2011-03-24 |
| US8513243B2 (en) | 2013-08-20 |
| KR20120085781A (ko) | 2012-08-01 |
| RU2551376C2 (ru) | 2015-05-20 |
| CN102695702A (zh) | 2012-09-26 |
| IL218403A0 (en) | 2012-04-30 |
| CA2771984A1 (en) | 2011-03-24 |
| JP2013505249A (ja) | 2013-02-14 |
| WO2011034934A1 (en) | 2011-03-24 |
| CN105820138A (zh) | 2016-08-03 |
| JP2015232006A (ja) | 2015-12-24 |
| ZA201202891B (en) | 2013-09-25 |
| TWI488853B (zh) | 2015-06-21 |
| US8362014B2 (en) | 2013-01-29 |
| RU2012115851A (ru) | 2013-10-27 |
| BR112012006252A2 (pt) | 2017-05-23 |
| EP2477972A1 (en) | 2012-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012003408A (es) | Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2. | |
| MX2011011511A (es) | Sal de abt-263 y fomas en estado solido de la misma. | |
| PH12015500297B1 (en) | Adoptosis-inducing agents for the treatment of cancer and immune and automoimmune disease | |
| PH12015502017A1 (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune disease | |
| MX2011007684A (es) | Agentes inductores de apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes. | |
| PH12012501071A1 (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| PH12015502792A1 (en) | Crystalline bromodomain inhibitors | |
| PH12018501264A1 (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| UA107706C2 (uk) | Апоптоз-індукуючий засіб для лікування раку й імунних і аутоімунних захворювань | |
| WO2010083441A3 (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| MX2009000285A (es) | Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas. | |
| TN2011000263A1 (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
| NZ598694A (en) | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use | |
| TNSN07093A1 (en) | Bicyclic amides as kinase inhibitors | |
| PL1687305T3 (pl) | Pochodne 1H-imidazochinolin jako inhibitory kinaz białkowych | |
| SI2324008T1 (sl) | 3,4-diarilpirazoli kot protein-kinazni inhibitorji | |
| SG10201406608YA (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| IL195142A (en) | Processed arylaimidazolone and triazolone, their preparation process, pharmaceutical preparations containing them for the treatment or prevention of diseases | |
| NZ596047A (en) | Stabilized lipid formulation of apoptosis promoter | |
| MX2014003408A (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1). | |
| UA92000C2 (en) | 1-benzylindole-2-carboxamide derivatives | |
| DE602007011975D1 (de) | Thiadiazolderivate zur behandlung neurodegenerativer krankheiten | |
| MY150931A (en) | Substituted oxazolidinones and their use | |
| UA102219C2 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы | |
| MX2012007325A (es) | Capsula de abt-263. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |